22 January 2016 in Diabetology & Metabolic Syndrome
The chronic care model (CCM) uses a systematic approach to restructure health care systems. The aim of this systematic review was to examine studies that evaluated different elements of the CCM in patients with type 2 diabetes mellitus (T2DM) and to assess the influence of the CCM on different clinical outcomes. There view was performed in the Medline and Cochrane Library electronic databases. The search was limited to randomized controlled trials conducted with T2DM patients. Studies were eligible for inclusion if they compared usual care with interventions that use done or more elements of the CCM and assessed the impact on clinical outcomes. After applying the eligibility criteria, 12 studies were included for data extraction. Of these, six showed evidence of effectiveness of the CCM for T2DM management in primary care as well as significant improvements in clinical outcomes. In the other six studies, no improvements regarding clinical outcomes were observed when comparing the intervention and control groups. Some limitations, such as a short follow-up period and a low number of patients, were observed. Some studies showed that the reorganization of health systems can improveT2DM care. However, it is possible that greater benefits could be obtained through combing all 6 elements of CCM.
1 July 2021 in Computers in Biology and Medicine
5 November 2013 in BioDrugs
1 February 2013 in Int. Journal of Clinical Pharmacology and Therapeutics
Despite the effectiveness of highly active antiretroviral therapy (HAART), many adverse events (AEs) are associated with the use of these drugs, thus affecting treatment adherence. The aim of this study was to evaluate AE incidence with the use of HAART and the relationship to treatment adherence. This was a retrospective observational study conducted with patients who experienced serious AEs related to HAART, resulting in the need to change the therapeutic regimen. To calculate adherence, the dates the patients received HAART were used. From January 2009 to December 2011, 168 AE cases associated with antiretroviral drugs were observed. Of the total study population, 58% of the patients were male. The side effects were associated with 12 drugs, of which 58.3% were nucleoside analogues reverse transcriptase inhibitors (NRTIs). In addition, 16.7% were non-nucleoside reversetranscriptase inhibitors (NNRTIs), and 25% were protease inhibitors (PIs). The NRTIs and PIs presented similar numbers of AEs, whereas the NNRTIs resulted in less than 50% of the reported AEs compared to other drug classes. The low adherence observed in patients with severe AEs that force treatment regimen change suggests that the occurrence of side effects could be one of the obstacles affecting the adherence and thus the effectiveness of HAART.
1 October 2009 in Archives of Endocrinology and Metabolism
OBJETIVO: Avaliar os resultados econômicos do seguimento farmacoterapêutico (SFT) em pacientes com diabetes melito tipo 2 em farmácias comunitárias privadas do sistema suplementar de Saúde. MÉTODOS: Foi realizado estudo clínico prospectivo com 161 pacientes separados em dois grupos, dos quais somente um recebeu SFT durante 12 meses. A partir dos resultados, foram calculados os dados de efetividade e os custos. O desfecho primário foi a avaliação econômica do SFT por meio da utilização de um indicador de efetividade (variação de hemoglobina glicada), relacionada aos custos do atendimento farmacêutico. Os desfechos secundários foram os valores de pressão arterial, circunferência abdominal e índice de massa corporal dos pacientes, que foram utilizados e relacionados a custos do atendimento do farmacêutico. RESULTADOS: Foi observada uma redução adicional de 1,3% da HbA1 no grupo que recebeu SFT em comparação ao grupo controle. Os custos anuais por paciente do grupo SFT relacionados à redução de 1% nos valores da HbA1 foram de R$ 78,83. Para melhoria no controle dos pacientes diabéticos tipo 2, esse recurso pode ser implementado com o investimento anual médio de R$ 456,05 por paciente, utilizando SFT e monitorização com testes de glicemia. CONCLUSÕES: É possível obter redução da HbA1 para níveis desejados por meio da utilização do SFT. Este pode ser considerado um recurso adicional para o alcance do controle metabólico, resultando, nesse estudo, em um custo de R$ 76,00 paciente/ano, para redução de 1% nos valores da HbA1.